DCGO on Nasdaq
DocGo Inc.
DocGo is leading the proactive healthcare revolution.1
Price unavailable
Last updated Oct 19, 2026.
Overview
Compare with Omada Health, Inc., GeneDx Holdings Corp. or Sharecare, or pick any stock.
- TickerDCGO on Nasdaq1
- IndustryServices-Health Services1
- HeadquartersNew York, New York1
- Incorporated inDE2
- Business address685 Third Avenue, 9Th Floor, New York, Ny 100172
- Filer categoryAccelerated filer, Smaller reporting company2
See how the biggest companies compare on our leaderboards
DocGo is leading the proactive healthcare revolution. We are democratizing access with our innovative care delivery platform that includes mobile health services, virtual care management and ambulance services. Our goal is to deliver healthcare at any address and help reshape the traditional healthcare system, driven by our mission to bring high quality, highly accessible care to all.3 From its latest annual report
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
-55.3%Operating margin4
-56.6%Net margin4
-47.7%Revenue growth, 20254
-126.7%Return on equity4
0.00×Debt to equity4
$29.9MFree cash flow4
What sells
Revenue by product, business segment and region, as the company reports it to the SEC.
Business segments
Transportation Services brought in 62% of the revenue DocGo Inc. broke down this way in fiscal 2025.
Business segments by year
| Business segments | 2023 | 2024 | 2025 |
|---|---|---|---|
| Transportation Services | $181.5M | $193.4M | $200.8M |
| Mobile Health Services | $442.8M | $423.1M | $121.4M |
Regions
United States brought in 83% of the revenue DocGo Inc. broke down this way in fiscal 2025.
Regions by year
| Regions | 2023 | 2024 | 2025 |
|---|---|---|---|
| United States | $571.9M | $558.8M | $268.3M |
| United Kingdoms | $52.4M | $57.8M | $53.9M |
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Research and development4¢$13.6M
- Other costs93¢$299.8M
- Income tax3¢$8.9M
Out of $322.2M in revenue.4 The company lost money this year.
Where each dollar of operating cash went, fiscal 2025
- Capital spending13¢$4.5M
- Share buybacks31¢$10.8M
- Kept or used elsewhere55¢$19.1M
Out of $34.5M of cash from operations.4
Financial statements
Every line of the income statement as filed: the last 3 fiscal years, latest first.4
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Revenues, net | $322.2M | $616.6M | $624.3M |
| Cost of revenues (exclusive of depreciation and amortization, which is shown separately below) | $223.4M | $403.0M | $428.9M |
| General and administrative | $133.4M | $138.8M | $137.2M |
| Depreciation and amortization | $15.7M | $15.9M | $16.4M |
| Legal and regulatory | $23.8M | $17.1M | $13.1M |
| Technology and development | $13.6M | $11.6M | $10.9M |
| Sales, advertising and marketing | $1.4M | $1.5M | $2.8M |
| Intangible asset impairment | $30.6M | $0 | $0 |
| Goodwill impairment | $58.2M | $0 | $0 |
| Total expenses | $500.2M | $587.9M | $609.2M |
| (Loss) income from operations | -$178.0M | $28.7M | $15.1M |
| Interest (expense) income, net | -$1.2M | -$1.9M | $1.7M |
| (Loss) gain on change in fair value of contingent consideration | -$2.1M | $9.4M | $1.4M |
| Finite-lived intangible asset impairment | $0 | -$8.3M | $0 |
| Loss on equity method investments | -$552.8K | -$316.0K | -$343.3K |
| Equity investment impairment | -$5.0M | $0 | $0 |
| Loss on remeasurement of operating and finance leases | -$42.4K | -$32.4K | -$866 |
| (Loss) gain on disposal of assets | -$39.7K | $23.7K | -$852.5K |
| Other (expense) income | -$532.4K | $228.7K | -$686.9K |
| Total other expense (income) | -$9.5M | -$939.7K | $1.2M |
| Net (loss) income before income tax expense | -$187.5M | $27.7M | $16.3M |
| Provision for income taxes | -$8.9M | -$14.4M | -$6.2M |
| Net (loss) income | -$196.4M | $13.4M | $10.0M |
| Net (loss) income attributable to noncontrolling interests | -$14.0M | -$6.6M | $3.2M |
| Net (loss) income attributable to stockholders of DocGo Inc. and Subsidiaries | -$182.4M | $20.0M | $6.9M |
| Unrealized gain on investments, net of tax | $85.6K | $0 | $0 |
| Foreign currency translation adjustment | $1.1M | -$263.0K | $743.7K |
| Total comprehensive (loss) income | -$181.2M | $19.7M | $7.6M |
| Net (loss) income per share attributable to DocGo Inc. and Subsidiaries - Basic (in Dollars per share) | -$1.84 | $0.20 | $0.07 |
| Weighted-average shares outstanding - Basic (in Shares) | 99.1M shares | 102.4M shares | 103.5M shares |
| Net income per share attributable to DocGo Inc. and Subsidiaries - Diluted (in Dollars per share) | -$1.84 | $0.18 | $0.06 |
| Weighted-average shares outstanding - Diluted (in Shares) | 99.1M shares | 109.4M shares | 105.6M shares |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 4 fiscal years (annual) or 4 quarters (quarterly), latest first.4
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $51.0M | $89.2M | $59.3M | |
| Accounts receivable, net of allowance for credit loss of $8,299,053 and $5,873,942 as of December 31, 2025 and December 31, 2024, respectively | $92.9M | $210.9M | ||
| Prepaid expenses | $4.8M | $4.0M | ||
| Other current assets | $3.7M | $338.7K | ||
| Total current assets | $152.4M | $304.5M | ||
| Property and equipment, net | $14.6M | $14.9M | ||
| Intangibles, net | $0 | $25.7M | ||
| Goodwill | $0 | $47.4M | $47.5M | |
| Restricted cash and cash equivalents | $1.5M | $18.1M | ||
| Restricted investments (amortized cost of $15,737,694 and $0 as of December 31, 2025 and December 31, 2024, respectively) | $15.8M | $0 | ||
| Operating lease right-of-use assets | $11.5M | $12.0M | ||
| Finance lease right-of-use assets | $17.4M | $15.3M | ||
| Investments | $0 | $5.5M | ||
| Deferred tax assets | $538.9K | $8.4M | ||
| Other assets | $3.4M | $3.7M | ||
| Total assets | $217.1M | $455.6M | $490.5M | |
| Accounts payable | $11.1M | $28.4M | ||
| Accrued liabilities | $42.8M | $49.9M | ||
| Line of credit | $0 | $30.0M | ||
| Notes payable, current | $51.7K | $12.5K | ||
| Due to seller | $337.0K | $28.7K | ||
| Contingent consideration, current | $3.0M | $5.0M | ||
| Operating lease liability, current | $4.7M | $3.8M | ||
| Finance lease liability, current | $5.5M | $4.7M | ||
| Total current liabilities | $67.5M | $121.8M | ||
| Notes payable, non-current | $183.8K | $5.2K | ||
| Contingent consideration, non-current | $4.8M | $0 | ||
| Operating lease liability, non-current | $7.6M | $8.6M | ||
| Finance lease liability, non-current | $11.2M | $10.0M | ||
| Total liabilities | $91.2M | $140.4M | ||
| Common stock ($0.0001 par value; 500,000,000 shares authorized as of December 31, 2025 and December 31, 2024; 98,640,059 and 101,910,883 shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively) | $9.9K | $10.2K | ||
| Additional paid-in-capital | $325.4M | $321.1M | ||
| Accumulated deficit | -$183.8M | -$1.4M | ||
| Accumulated other comprehensive income | $2.4M | $1.2M | ||
| Total stockholders equity attributable to DocGo Inc. and Subsidiaries | $144.0M | $320.9M | ||
| Noncontrolling interests | -$18.1M | -$5.7M | ||
| Total stockholders equity | $125.9M | $315.2M | $305.2M | $278.9M |
| Total liabilities and stockholders equity | $217.1M | $455.6M | ||
| Accounts receivable, net of allowance | $8.3M | $5.9M | ||
| Restricted investments amortized cost | $17.2M | |||
| Common stock, par value (in Dollars per share) | $0.00 | $0.00 | ||
| Common stock, shares authorized (in shares) | 500.0M shares | 500.0M shares | ||
| Common stock, shares issued (in shares) | 98.6M shares | 101.9M shares | ||
| Common stock, shares outstanding (in shares) | 98.6M shares | 101.9M shares |
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $51.0M | $89.2M | $59.3M | |
| Accounts receivable, net of allowance for credit loss of $8,299,053 and $5,873,942 as of December 31, 2025 and December 31, 2024, respectively | $92.9M | $210.9M | ||
| Prepaid expenses | $4.8M | $4.0M | ||
| Other current assets | $3.7M | $338.7K | ||
| Total current assets | $152.4M | $304.5M | ||
| Property and equipment, net | $14.6M | $14.9M | ||
| Intangibles, net | $0 | $25.7M | ||
| Goodwill | $0 | $47.4M | $47.5M | |
| Restricted cash and cash equivalents | $1.5M | $18.1M | ||
| Restricted investments (amortized cost of $15,737,694 and $0 as of December 31, 2025 and December 31, 2024, respectively) | $15.8M | $0 | ||
| Operating lease right-of-use assets | $11.5M | $12.0M | ||
| Finance lease right-of-use assets | $17.4M | $15.3M | ||
| Investments | $0 | $5.5M | ||
| Deferred tax assets | $538.9K | $8.4M | ||
| Other assets | $3.4M | $3.7M | ||
| Total assets | $217.1M | $455.6M | $490.5M | |
| Accounts payable | $11.1M | $28.4M | ||
| Accrued liabilities | $42.8M | $49.9M | ||
| Line of credit | $0 | $30.0M | ||
| Notes payable, current | $51.7K | $12.5K | ||
| Due to seller | $337.0K | $28.7K | ||
| Contingent consideration, current | $3.0M | $5.0M | ||
| Operating lease liability, current | $4.7M | $3.8M | ||
| Finance lease liability, current | $5.5M | $4.7M | ||
| Total current liabilities | $67.5M | $121.8M | ||
| Notes payable, non-current | $183.8K | $5.2K | ||
| Contingent consideration, non-current | $4.8M | $0 | ||
| Operating lease liability, non-current | $7.6M | $8.6M | ||
| Finance lease liability, non-current | $11.2M | $10.0M | ||
| Total liabilities | $91.2M | $140.4M | ||
| Common stock ($0.0001 par value; 500,000,000 shares authorized as of December 31, 2025 and December 31, 2024; 98,640,059 and 101,910,883 shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively) | $9.9K | $10.2K | ||
| Additional paid-in-capital | $325.4M | $321.1M | ||
| Accumulated deficit | -$183.8M | -$1.4M | ||
| Accumulated other comprehensive income | $2.4M | $1.2M | ||
| Total stockholders equity attributable to DocGo Inc. and Subsidiaries | $144.0M | $320.9M | ||
| Noncontrolling interests | -$18.1M | -$5.7M | ||
| Total stockholders equity | $125.9M | $315.2M | $305.2M | $278.9M |
| Total liabilities and stockholders equity | $217.1M | $455.6M | ||
| Accounts receivable, net of allowance | $8.3M | $5.9M | ||
| Restricted investments amortized cost | $17.2M | |||
| Common stock, par value (in Dollars per share) | $0.00 | $0.00 | ||
| Common stock, shares authorized (in shares) | 500.0M shares | 500.0M shares | ||
| Common stock, shares issued (in shares) | 98.6M shares | 101.9M shares | ||
| Common stock, shares outstanding (in shares) | 98.6M shares | 101.9M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 3 fiscal years, latest first.4
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Net (loss) income | -$196.4M | $13.4M | $10.0M |
| Depreciation expense | $4.9M | $5.6M | $4.8M |
| Amortization of intangible assets | $5.6M | $5.7M | $5.2M |
| Amortization of finance lease right-of-use assets | $5.2M | $4.6M | $6.4M |
| Loss (gain) on disposal of assets | $39.7K | -$23.7K | $852.5K |
| Deferred income tax | $7.7M | $3.5M | -$2.0M |
| Accretion of discount related to restricted investments | -$309.8K | $0 | $0 |
| Loss on equity method investments | $552.8K | $316.0K | $343.3K |
| Bad debt expense | $12.0M | $5.2M | $3.6M |
| Stock-based compensation | $17.4M | $13.6M | $21.0M |
| Loss on remeasurement of operating and finance leases | $42.4K | $32.4K | $866 |
| Loss on liquidation of business | $0 | $0 | $70.3K |
| Intangible asset impairment | $30.6M | $8.3M | $0 |
| Goodwill impairment | $58.2M | $0 | $0 |
| Equity investment impairment | $5.0M | $0 | $0 |
| Loss (gain) on change in fair value of contingent consideration | $2.1M | -$9.4M | -$1.4M |
| Accounts receivable | $112.5M | $41.3M | -$160.5M |
| Prepaid expenses and other current assets | -$3.4M | $13.0M | -$10.8M |
| Other assets | $409.2K | -$1.4M | $1.1M |
| Accounts payable | -$17.6M | $8.3M | -$2.1M |
| Accrued liabilities | -$10.4M | -$41.9M | $59.0M |
| Operating lease liabilities and right-of-use assets | $200.2K | $32.8K | $0 |
| Net cash provided by (used in) operating activities | $34.5M | $70.1M | -$64.5M |
| Purchase of property and equipment | -$4.5M | -$3.6M | -$7.3M |
| Purchase of intangibles | -$2.9M | -$2.0M | -$2.5M |
| Acquisition of businesses, net of cash acquired | -$16.4M | $0 | -$20.2M |
| Purchase of restricted investments | -$28.6M | $0 | $0 |
| Purchase of equity method investments | -$4.8K | -$310.4K | -$298.9K |
| Purchase of equity securities | $0 | -$5.0M | $0 |
| Proceeds from sale and maturity of restricted investments | $13.2M | $0 | $0 |
| Proceeds from disposal of property and equipment | $202.2K | $274.4K | $747.1K |
| Net cash used in investing activities | -$39.1M | -$10.7M | -$29.6M |
| Proceeds from revolving credit line | $0 | $45.0M | $25.0M |
| Repayments of revolving credit line | -$30.0M | -$40.0M | $0 |
| Proceeds from notes payable | $258.7K | $0 | $0 |
| Repayments of notes payable | -$41.2K | -$52.0K | -$25.9K |
| Due to seller | -$877.7K | -$3.1M | -$13.6M |
| Acquisition of noncontrolling interest | $0 | -$1.8M | $0 |
| Earnout payments on contingent liabilities | -$2.0M | -$3.6M | -$5.3M |
| Distributions paid to noncontrolling interest | -$175.8K | -$1.3M | $0 |
| Proceeds from exercise of stock options | $0 | $26.3K | $1.6M |
| Payments for taxes related to shares withheld for employee taxes | -$1.8M | -$1.2M | -$2.3M |
| Common stock repurchased | -$10.8M | -$13.8M | $0 |
| Payments on obligations under finance lease | -$5.4M | -$4.3M | -$4.3M |
| Net cash (used in) provided by financing activities | -$50.8M | -$24.2M | $1.1M |
| Effect of exchange rate changes on cash and cash equivalents | $595.8K | -$190.6K | $1.1M |
| Net (decrease) increase in cash, cash equivalents, restricted cash and restricted cash equivalents | -$54.9M | $35.1M | -$91.9M |
| Cash paid for interest | $1.7M | $2.1M | $250.1K |
| Cash paid for interest on finance lease liabilities | $958.6K | $769.0K | $600.2K |
| Cash paid for income taxes, net of refunds | $6.5M | $5.9M | $10.3M |
| Right-of-use assets obtained in exchange for lease liabilities | $11.7M | $14.0M | $7.6M |
| Remeasurement of finance lease right-of-use asset due to lease modification | $0 | $300.0K | $0 |
| Property and equipment in accounts payable | $52.9K | $221.6K | $271.3K |
| CRMS True-up Payment through issuance of stock | $0 | $1.8M | $0 |
| Receivables exchanged for trade credits | $0 | $0 | $1.5M |
| Pre-acquisition receivables written off through due to seller | $0 | $4.7M | $0 |
No quarter-by-quarter statement was filed.
Leadership
Who has led DocGo Inc., and when. Pick a name to see everywhere that person has worked.
Chief financial officer
Chief operating officer
2025
- Chief executive officerAnthony Capone Mar 20, 2023 to Sep 6, 202311
- Chief executive officerLee Bienstock Sep 19, 2023 to now12
- Chief executive officerStanley Vashovsky Nov 9, 2021 to Dec 19, 202213
- PresidentLee Bienstock Aug 17, 2023 to Aug 17, 202314
- PresidentAnthony Capone Nov 9, 2021 to May 16, 202315
- Chief financial officerAdriaan Stephanus Oberholzer Nov 9, 2021 to May 16, 202316
- Chief financial officerNorman Rosenberg Nov 9, 2021 to now17
- Chief financial officerMichael J. Burdiek Oct 14, 2020 to Oct 14, 202018
- Chief operating officerLee Bienstock Apr 26, 2022 to Aug 17, 202319
Board members and other officers (20)
- OfficerAdriaan Stephanus Oberholzer May 25, 2023 to Sep 1, 202320
- Chief Compliance OfficerStephen Sugrue Mar 21, 2022 to now21
- EVP, Corporate DevelopmentMichael J. Burdiek Aug 25, 2021 to Aug 25, 202122
- CMO, Ambulnz Holdings, LLCMark Do Merlin Nov 9, 2021 to May 2, 202223
- Chief Compliance OfficerMichael S. Witkowski Nov 9, 2021 to Jan 27, 202224
- OfficerGaro Sarkis Sarkissian Oct 14, 2020 to Aug 25, 202118
- Executive Vice PresidentRichard K. Vitelle Oct 14, 2020 to Aug 25, 202118
- Board memberLee Bienstock May 13, 2024 to now25
- Board memberStephen K. M.d. Klasko Oct 1, 2024 to now26
- Board memberEtalvina Leite Nov 16, 2022 to now27
- Board memberChristopher Fillo Nov 9, 2021 to Jan 27, 202228
- Board memberEly D. Tendler Nov 9, 2021 to now29
- Board memberIra Smedra Nov 9, 2021 to now30
- Board memberStanley Vashovsky Nov 9, 2021 to Mar 18, 202413
- Board memberSteven Katz Nov 9, 2021 to Mar 18, 202431
- Board memberAndrew Flett Oct 14, 2020 to Oct 14, 202032
- Board memberKyle A. Messman Oct 14, 2020 to Oct 14, 202033
- Board memberMark Licht Oct 14, 2020 to Oct 14, 202034
- Board memberMichael J. Burdiek Oct 14, 2020 to now18
- General counselEly D. Tendler Nov 9, 2021 to now29
Former names
- Motion Acquisition Corp.Aug 28, 2020 to Nov 5, 20212
Timeline
Filings
358 filings to the SEC since October 2021: 7 annual reports, 17 quarterly reports, 64 major events, 165 insider forms, 22 large holders, 83 other. The latest 20:
- Oct 5, 20268-K EDGAR
- Aug 17, 202610-Q EDGAR
- Aug 17, 20268-K EDGAR
- Aug 10, 2026NT 10-Q EDGAR
- Jul 31, 20268-K EDGAR
- Jul 28, 2026SCHEDULE 13G/A EDGAR
- Jul 2, 20268-K EDGAR
- Jun 18, 20268-K EDGAR
- May 14, 20264 EDGAR
- May 11, 20268-K EDGAR
- May 11, 202610-Q EDGAR
- Apr 22, 20268-K EDGAR
- Apr 22, 2026ARS EDGAR
- Apr 22, 2026DEFA14A DEFINITIVE ADDITIONAL MATERIALS EDGAR
- Apr 22, 2026DEF 14A PROXY STATEMENT EDGAR
- Apr 10, 2026PRE 14A PROXY STATEMENT EDGAR
- Mar 31, 20264 EDGAR
- Mar 26, 2026SCHEDULE 13G/A EDGAR
- Mar 17, 2026S-8 EDGAR
- Mar 16, 20268-K EDGAR
The 358 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Insider trades
35 open-market trades by officers, directors and large owners since October 2021: 12 buys and 23 sales. Grants, option exercises and gifts are left out.
| Date | Who | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Dec 15, 2025 | Tendler Ely DGeneral Counsel and Secretary | Sale | 16,850 | $0.91 | $15.3K | Form 4 |
| May 23, 2025 | Burdiek Michael JDirector | Buy | 10,000 | $1.33 | $13.3K | Form 4 |
| May 15, 2025 | Burdiek Michael JDirector | Buy | 15,000 | $1.43 | $21.4K | Form 4 |
| May 14, 2025 | Klasko Stephen K. M.D.Director | Buy | 15,000 | $1.49 | $22.4K | Form 4 |
| May 14, 2025 | Sugrue StephenChief Compliance Officer | Buy | 10,000 | $1.44 | $14.4K | Form 4 |
| May 14, 2025 | ROSENBERG NORMANCFO and Treasurer | Buy | 15,000 | $1.47 | $22.1K | Form 4 |
| May 14, 2025 | Bienstock LeeChief Executive Officer | Buy | 15,000 | $1.54 | $23.1K | Form 4 |
| Dec 17, 2024 | Leite EtalvinaDirector | Sale | 16,500 | $4.34 | $71.6K | Form 4 |
| Dec 16, 2024 | Tendler Ely DGeneral Counsel and Secretary | Sale | 23,088 | $4.44 | $102.5K | Form 4 |
| May 14, 2024 | Burdiek Michael JDirector | Buy | 10,000 | $3.40 | $34.0K | Form 4 |
| May 13, 2024 | Tendler Ely DGeneral Counsel and Secretary | Buy | 10,000 | $3.13 | $31.3K | Form 4 |
| May 13, 2024 | Bienstock LeeChief Executive Officer | Buy | 25,000 | $3.15 | $78.8K | Form 4 |
| Mar 15, 2024 | KATZ STEVENDirector | Buy | 13,500 | $3.64 | $49.1K | Form 4 |
| Mar 14, 2024 | ROSENBERG NORMANCFO and Treasurer | Buy | 10,000 | $3.61 | $36.1K | Form 4 |
| Mar 14, 2024 | Burdiek Michael JDirector | Buy | 10,000 | $3.61 | $36.1K | Form 4 |
| Nov 28, 2023 | Sugrue StephenChief Compliance Officer | Sale | 2,859 | $5.75 | $16.4K | Form 4 |
| Oct 16, 2023 | Bienstock LeeChief Executive Officer | Sale | 1,667 | $5.89 | $9.8K | Form 4 |
| Oct 2, 2023 | Tendler Ely DGeneral Counsel and Secretary | Sale | 10,000 | $5.29 | $52.9K | Form 4 |
| Sep 15, 2023 | Bienstock LeeChief Executive Officer | Sale | 1,667 | $6.32 | $10.5K | Form 4 |
| Sep 15, 2023 | Tendler Ely DGeneral Counsel and Secretary | Sale | 10,000 | $5.91 | $59.1K | Form 4 |
All 35 trades can be filtered by person here when JavaScript is on.
From Forms 4 filed with the SEC.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- BlackRockSCHEDULE 13G/A, 1 filing Jul 28, 202635
- VANGUARD GROUP INCSCHEDULE 13G/A, 2 filings Apr 30, 2025 to Mar 26, 202636
- Stanley VashovskySCHEDULE 13D/A, 3 filings Nov 15, 2021 to Feb 26, 202637
- James E. FlynnSCHEDULE 13G/A, 4 filings Oct 18, 2023 to Feb 13, 202538
- Hood River Capital Management LLCSC 13G/A, 3 filings Jan 25, 2023 to Mar 1, 202439
- MOORE CAPITAL MANAGEMENT, LPSC 13G/A, 3 filings Nov 15, 2021 to Feb 14, 202340
- Radcliffe Capital Management, L.P.SC 13G/A, 1 filing Feb 14, 202241
- ADAGE CAPITAL PARTNERS GP, L.L.C.SC 13G/A, 1 filing Feb 10, 202242
- Weiss Asset Management LPSC 13G/A, 1 filing Feb 4, 202243
- Linden Capital L.P.SC 13G/A, 1 filing Feb 2, 202244
Held by these funds
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.
| Fund | Shares | Value | Share of the fund | Change |
|---|---|---|---|---|
| Vanguard Capital Management LLC | 3,728,207 | $1.9M | 0.0% | +45,639 |
| P.a.w. Capital Corp | 3,505,000 | $1.8M | 1.4% | +500,000 |
| Knott David M Jr | 2,670,850 | $1.4M | 0.7% | No change |
| Peapod Lane Capital LLC | 2,500,118 | $1.3M | 0.9% | +1,370,924 |
| Citadel Advisors LLC | 2,353,610 | $1.2M | 0.0% | −146,390 |
| Renaissance Technologies LLC | 2,254,370 | $1.2M | 0.0% | +744,009 |
| S Squared Technology, LLC | 2,055,271 | $1.1M | 0.3% | No change |
| Aqr Capital Management LLC | 1,708,962 | $882.0K | 0.0% | +973,704 |
| Moore Capital Management, LP | 1,465,000 | $756.1K | 0.0% | No change |
| BlackRock, Inc. | 1,454,063 | $750.4K | 0.0% | −4,911,965 |
| Isthmus Partners, LLC | 1,191,977 | $615.2K | 0.1% | +178,921 |
| Geode Capital Management, LLC | 1,065,850 | $550.3K | 0.0% | −1,344,219 |
| Franklin Resources Inc | 840,645 | $433.9K | 0.0% | +235,522 |
| RBF Capital, LLC | 650,000 | $335.5K | 0.0% | New |
| Vanguard Fiduciary Trust Co | 603,449 | $311.4K | 0.0% | +55,461 |
| Charles Schwab Investment Management Inc | 436,021 | $225.0K | 0.0% | −236,865 |
| State Street Corp | 421,319 | $217.4K | 0.0% | −1,545,524 |
| Two Sigma Investments, LP | 343,711 | $177.4K | 0.0% | New |
| Mackenzie Financial Corp | 338,877 | $174.9K | 0.0% | +314,891 |
| Brown Advisory Inc | 338,515 | $174.7K | 0.0% | No change |
| Marquette Asset Management, LLC | 338,344 | $174.6K | 0.0% | New |
| UBS Group AG | 333,804 | $172.2K | 0.0% | +230,178 |
| XTX Topco Ltd | 278,275 | $143.6K | 0.0% | +199,474 |
| Summit Financial, LLC | 268,987 | $138.8K | 0.0% | New |
| Vanguard Portfolio Management LLC | 260,241 | $134.3K | 0.0% | −519,020 |
13F reports cover disclosed long positions in U.S. stocks only.
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1SEC EDGARDocGo Inc. filings on SEC EDGAR
- 2SEC EDGARDocGo Inc. filings on SEC EDGAR
- 3
- 4SEC EDGARDocGo Inc. 10-K for fiscal 2025
- 5SEC EDGARDocGo Inc. 10-K for fiscal 2020
- 6SEC EDGARDocGo Inc. 10-K for fiscal 2021
- 7SEC EDGARDocGo Inc. 10-K for fiscal 2022
- 8SEC EDGARDocGo Inc. 10-K for fiscal 2021
- 9SEC EDGARDocGo Inc. 10-Q for fiscal 2026
- 10SEC EDGARDocGo Inc. 10-Q for fiscal 2026
- 11
- 12
- 13
- 14SEC EDGARLee Bienstock, President
- 15SEC EDGARAnthony Capone, President
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25SEC EDGARLee Bienstock, Board member
- 26SEC EDGARStephen K. M.d. Klasko, Board member
- 27SEC EDGAREtalvina Leite, Board member
- 28SEC EDGARChristopher Fillo, Board member
- 29SEC EDGAREly D. Tendler, Board member
- 30SEC EDGARIra Smedra, Board member
- 31SEC EDGARSteven Katz, Board member
- 32SEC EDGARAndrew Flett, Board member
- 33SEC EDGARKyle A. Messman, Board member
- 34SEC EDGARMark Licht, Board member
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44